Enlivex Selected to Present at Israeli BioMed 2025 Conference
Enlivex Therapeutics (NASDAQ: ENLV) has been selected to present at the Israeli BioMed 2025 Conference in Tel Aviv from May 21-23, 2025. The presentation, titled "Enlivex鈥擧arnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases," will focus on their cell therapy product 础濒濒辞肠别迟谤补鈩�.
础濒濒辞肠别迟谤补鈩� is a universal, off-the-shelf cell therapy designed to reset macrophages to their homeostatic state. The company is currently conducting multiple Phase I/II trials, with promising interim results in moderate knee osteoarthritis showing significant improvements including:
- 47% reduction in pain
- 46% improvement in joint function
- 40% decrease in stiffness
Additional trial readouts are expected in 2025.
Enlivex Therapeutics (NASDAQ: ENLV) 猫 stata selezionata per presentare al Israeli BioMed 2025 Conference a Tel Aviv dal 21 al 23 maggio 2025. La presentazione, intitolata "Enlivex鈥擲fruttare il potere naturale di guarigione dei macrofagi per trattare le malattie infiammatorie", si concentrer脿 sul loro prodotto di terapia cellulare 础濒濒辞肠别迟谤补鈩�.
础濒濒辞肠别迟谤补鈩� 猫 una terapia cellulare universale, pronta all鈥檜so, progettata per riportare i macrofagi al loro stato omeostatico. L鈥檃zienda sta attualmente conducendo diversi studi di Fase I/II, con risultati intermedi promettenti nell鈥檕steoartrite moderata del ginocchio che mostrano miglioramenti significativi tra cui:
- Riduzione del dolore del 47%
- Miglioramento della funzione articolare del 46%
- Diminuzione della rigidit脿 del 40%
Sono previsti ulteriori risultati degli studi nel 2025.
Enlivex Therapeutics (NASDAQ: ENLV) ha sido seleccionada para presentar en la Conferencia Israeli BioMed 2025 en Tel Aviv del 21 al 23 de mayo de 2025. La presentaci贸n, titulada "Enlivex鈥擜provechando el poder natural de curaci贸n de los macr贸fagos para tratar enfermedades inflamatorias", se centrar谩 en su producto de terapia celular 础濒濒辞肠别迟谤补鈩�.
础濒濒辞肠别迟谤补鈩� es una terapia celular universal y lista para usar, dise帽ada para restablecer los macr贸fagos a su estado homeost谩tico. La compa帽铆a est谩 actualmente llevando a cabo m煤ltiples ensayos de Fase I/II, con resultados interinos prometedores en osteoartritis moderada de rodilla que muestran mejoras significativas incluyendo:
- Reducci贸n del dolor del 47%
- Mejora del funcionamiento articular del 46%
- Disminuci贸n de la rigidez del 40%
Se esperan m谩s resultados de los ensayos en 2025.
Enlivex Therapeutics (NASDAQ: ENLV)電� 2025雲� 5鞗� 21鞚茧秬韯� 23鞚缄箤歆� 韰旍晞牍勲笇鞐愳劀 鞐措Μ電� Israeli BioMed 2025 旎嵓霟办姢鞐愳劀 氚滍憸鞛愲 靹犾爼霅橃棃鞀惦媹雼�. "Enlivex鈥旍椉歃濎劚 歆堩櫂 旃橂毳� 鞙勴暅 雽�鞁濎劯韽潣 鞛愳棸 旃橃湢霠� 頇滌毄"鞚措澕電� 鞝滊鞚� 氚滍憸電� 攴鸽摛鞚� 靹疙彫 旃橂鞝� 础濒濒辞肠别迟谤补鈩�鞐� 齑堨爯鞚� 毵烄稖 鞓堨爼鞛呺媹雼�.
础濒濒辞肠别迟谤补鈩㈦姅 雽�鞁濎劯韽ゼ 頃儊靹� 靸來儨搿� 鞛劋鞝曧晿霃勲 靹り硠霅� 氩旍毄 歃夓嫓 靷毄 臧�電ロ暅 靹疙彫 旃橂鞝滌瀰雼堧嫟. 須岇偓電� 順勳灛 鞐煬 雼硠 I/II 鞛勳儊鞁滍棙鞚� 歆勴枆 欷戩澊氅�, 欷戨摫霃� 氍措 瓿磤鞝堨椉鞐愳劀 鞙犽頃� 欷戧皠 瓴瓣臣毳� 氤挫澊氅� 鞙犾潣氙疙暅 臧滌劆鞚� 雮橅儉雮搓碃 鞛堨姷雼堧嫟:
- 韱奠 47% 臧愳唽
- 甏�鞝� 旮半姤 46% 頄レ儊
- 瓴届 40% 臧愳唽
於旉皜 鞛勳儊 瓴瓣臣電� 2025雲勳棎 氚滍憸霅� 鞓堨爼鞛呺媹雼�.
Enlivex Therapeutics (NASDAQ : ENLV) a 茅t茅 s茅lectionn茅e pour pr茅senter lors de la Conf茅rence Israeli BioMed 2025 脿 Tel Aviv du 21 au 23 mai 2025. La pr茅sentation, intitul茅e 芦 Enlivex 鈥� Exploiter le pouvoir naturel de gu茅rison des macrophages pour traiter les maladies inflammatoires 禄, portera sur leur produit de th茅rapie cellulaire 础濒濒辞肠别迟谤补鈩�.
础濒濒辞肠别迟谤补鈩� est une th茅rapie cellulaire universelle, pr锚te 脿 l鈥檈mploi, con莽ue pour r茅initialiser les macrophages 脿 leur 茅tat hom茅ostatique. La soci茅t茅 m猫ne actuellement plusieurs essais de phase I/II, avec des r茅sultats interm茅diaires prometteurs dans l鈥檃rthrose mod茅r茅e du genou montrant des am茅liorations significatives telles que :
- R茅duction de la douleur de 47 %
- Am茅lioration de la fonction articulaire de 46 %
- Diminution de la raideur de 40 %
D鈥檃utres r茅sultats d鈥檈ssais sont attendus en 2025.
Enlivex Therapeutics (NASDAQ: ENLV) wurde ausgew盲hlt, auf der Israeli BioMed 2025 Konferenz in Tel Aviv vom 21. bis 23. Mai 2025 zu pr盲sentieren. Die Pr盲sentation mit dem Titel 鈥濫nlivex 鈥� Nutzung der nat眉rlichen Heilkr盲fte von Makrophagen zur Behandlung entz眉ndlicher Erkrankungen鈥� wird sich auf ihr Zelltherapieprodukt 础濒濒辞肠别迟谤补鈩� konzentrieren.
础濒濒辞肠别迟谤补鈩� ist eine universelle, sofort verf眉gbare Zelltherapie, die darauf ausgelegt ist, Makrophagen in ihren hom枚ostatischen Zustand zur眉ckzuversetzen. Das Unternehmen f眉hrt derzeit mehrere Phase I/II-Studien durch, mit vielversprechenden Zwischenergebnissen bei moderater Kniearthrose, die signifikante Verbesserungen zeigen, darunter:
- 47 % Schmerzlinderung
- 46 % Verbesserung der Gelenkfunktion
- 40 % Verringerung der Steifheit
Weitere Studienergebnisse werden f眉r 2025 erwartet.
- None.
- None.
Presentation to highlight 础濒濒辞肠别迟谤补鈩� and the therapeutic potential of macrophage reprogramming in inflammatory diseases
Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the 鈥淐ompany鈥�), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company has been selected to present at the upcoming Israeli BioMed 2025 Conference, taking place May 21鈥�23, 2025 in Tel Aviv, Israel. The Company鈥檚 presentation is titled 鈥淓nlivex鈥擧arnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases鈥� and will be delivered by the Company鈥檚 CEO on May 21st as part of the session 鈥淧ersonalized Pathways; Genetic and Cellular Based Therapies for Rare and Complex Diseases鈥�.
础濒濒辞肠别迟谤补鈩�, Enlivex鈥檚 universal, off-the-shelf cell therapy, is designed to reset macrophages鈥攌ey immune cells鈥攖o their homeostatic, or 鈥渂alanced,鈥� state. Non-homeostatic macrophages are implicated in a broad range of chronic and life-threatening diseases, and 础濒濒辞肠别迟谤补鈩⑩�檚 unique reprogramming capability may offer a promising strategy for immune system rebalancing and disease resolution.
Enlivex is currently advancing a broad clinical pipeline with 础濒濒辞肠别迟谤补鈩�, including multiple Phase I/II trials in osteoarthritis and psoriatic arthritis. Recent data from a six-month interim readout in moderate knee osteoarthritis showed statistically significant reductions in pain (
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing 础濒濒辞肠别迟谤补鈩�, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit聽.
Safe Harbor Statement:聽 This press release contains forward-looking statements, which may be identified by words such as 鈥渆xpects,鈥� 鈥減lans,鈥� 鈥減rojects,鈥� 鈥渨ill,鈥� 鈥渕ay,鈥� 鈥渁nticipates,鈥� 鈥渂elieves,鈥� 鈥渟hould,鈥� 鈥渨ould鈥�, 鈥渃ould,鈥� 鈥渋ntends,鈥� 鈥渆stimates,鈥� 鈥渟uggests,鈥� 鈥渉as the potential to鈥� and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA聽罢惭听programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.聽 Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect聽Enlivex鈥檚聽business and prospects, including the risks that聽Enlivex聽may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA聽罢惭听product line could also be affected by聽a number of聽other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.聽 In addition to the risk factors described above, investors should consider the economic, competitive, governmental,聽technological聽and other factors discussed in聽Enlivex鈥檚聽filings with the Securities and Exchange Commission, including in the Company鈥檚 most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.聽 The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
听听听
FAQ
What is 础濒濒辞肠别迟谤补鈩� and how does it work?
What are the latest clinical results for ENLV's 础濒濒辞肠别迟谤补鈩� in osteoarthritis?
What clinical trials is Enlivex (ENLV) currently conducting?
When and where is Enlivex presenting at the Israeli BioMed 2025 Conference?
